Nurix Therapeutics, Inc. (NRIX) community

NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30

Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value

$15.48−0.12 (-0.77%)

Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%

Community

Notes and questions about Nurix Therapeutics from other investors

No posts about NRIX yet

Discussion is coming to every stock. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Where these numbers come from

Parsed from the XBRL in Nurix Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NRIX.

Compare: NRIX vs ARVN · NRIX vs PTGX · NRIX vs RARE · NRIX vs HCM · NRIX vs MIRM

Revenue growth738.8% · median 15.8%

Operating margin41.3% · median -64.0%

Net margin42.0% · median -51.7%

Company	Revenue	Growth
RARE	$730.00M	+15.8%
NRIX	$701.94M	+738.8%
MIRM	$618.07M	+44.0%
PTGX	$551.69M	+163.7%
ARVN	$316.70M	-15.0%
HCM	$204.89M	-4.3%

Company

Next earnings (est.): Jan 27, 2027, after close
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: November 30
Employees: 317
Held by institutions: 100.0%
Auditor: PricewaterhouseCoopers LLP
SEC CIK: 1549595

Advertisement
300 × 250

See a number that looks wrong?